Market Cap $10 M -- Cash $7 M-- Shares Out 4.7 M --NASH Phase 2 results imminent ($35+ BILLION MKT with no approved treatment to date -- Additional 3 Phase 3 programs in different indications ongoing .. this low float could be the next 10 bagger and even then it would be cheap if everything goes well . Market Cap $10 M Cash $7.1 M Price $2.72 Shares Out 4.7 M Presentation https://content.equisolve.net/canfite/media/21ad6a7941d2eadbcf05c0b7ec2d8475.pdf Letter to Shareholders https://finance.yahoo.com/news/fite-ceo-issues-letter-shareholders-120000180.html Q1 2020: Topline results from NASH Phase II study expected Advanced stage clinical pipeline positioned to potentially generate more non-dilutive funding through out-licensing distribution agreements Two Phase III studies enrolling in psoriasis and rheumatoid arthritis Advanced Stage Drug Maker in Multi-Billion Dollar Market Receives Buy Rating & $9 Price Target from Dawson James http://www.canfinfo.com/
